The enzyme phosphodiesterase 10A (PDE10A) regulates the activity of striatal, medium spiny neurons (MSNs), which are divided into a behaviorally stimulating, Gs-coupled D 1 receptor-expressing "direct" pathway and a behaviorally suppressant, Gi-coupled D 2 receptor-expressing "indirect" pathway. Activating both pathways, PDE10A inhibitors (PDE10AIs) combine functional characteristics of D 2 antagonists and D 1 agonists. While the effects of PDE10AIs on spontaneous and stimulated behavior have been extensively reported, the present study investigates their effects on suppressed behavior under various conditions of reduced dopaminergic neurotransmission: blockade of D 1 receptors with SCH-23390, blockade of D 2 receptors with haloperidol, or depletion of dopamine with RO-4-1284 or reserpine. In rats, PDE10AIs displayed relatively low cataleptic activity per se. After blocking D 1 receptors, however, they induced pronounced catalepsy at low doses close to those required for inhibition of apomorphineinduced behavior; slightly higher doses resulted in behavioral stimulant effects, counteracting the catalepsy. PDE10AIs also counteracted catalepsy and related behaviors induced by D 2 receptor blockade or dopamine depletion; catalepsy was replaced by behavioral stimulant effects under the latter but not the former condition. Similar interactions were observed at the level of locomotion in mice. At doses close to those inhibiting D-amphetamine-induced hyperlocomotion, PDE10AIs reversed hypolocomotion induced by D 1 receptor blockade or dopamine depletion but not hypolocomotion induced by D 2 receptor blockade. It is concluded that PDE10AIs stimulate or inhibit motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways.
D 2 antagonists and D 1 agonists. While the effects of PDE10AIs on spontaneous and stimulated behavior have been extensively reported, the present study investigates their effects on suppressed behavior under various conditions of reduced dopaminergic neurotransmission: blockade of D 1 receptors with SCH-23390, blockade of D 2 receptors with haloperidol, or depletion of dopamine with RO-4-1284 or reserpine. In rats, PDE10AIs displayed relatively low cataleptic activity per se. After blocking D 1 receptors, however, they induced pronounced catalepsy at low doses close to those required for inhibition of apomorphineinduced behavior; slightly higher doses resulted in behavioral stimulant effects, counteracting the catalepsy. PDE10AIs also counteracted catalepsy and related behaviors induced by D 2 receptor blockade or dopamine depletion; catalepsy was replaced by behavioral stimulant effects under the latter but not the former condition. Similar interactions were observed at the level of locomotion in mice. At doses close to those inhibiting D-amphetamine-induced hyperlocomotion, PDE10AIs reversed hypolocomotion induced by D 1 receptor blockade or dopamine depletion but not hypolocomotion induced by D 2 receptor blockade. It is concluded that PDE10AIs stimulate or inhibit motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways.
Abbreviations AE, adverse event; cAMP, cyclic adenosine monophosphate; cGMP, cyclic guanosine monophosphate; CL, confidence limits; EPS, extrapyramidal symptoms; i.v., intravenous; JNJ-42314415, 3-[6-(2-methoxyethyl)pyridin-3-yl]-2-methyl-8-morpholin-4-ylimidazo[1,2-a]pyrazine; MP-10, 2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl}quinoline; MSNs, medium spiny neurons; PDE10AI, phosphodiesterase 10A inhibitor; 6, pyrrolidin-1-yl]quinazoline; RO-4-1284, 2-ethyl-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol; PDE, phosphodiesterase; PKA, protein kinase A; SCH-23390, 8-chloro-3-methyl-5-phenyl-2,3,4, 5-tetrahydro-1H-3-benzazepin-7-ol; SKF-82958, 6-chloro-1-phenyl-3-prop-2-en-1-yl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; TP-10, 2-({4-[4-pyridin-4 -yl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]phenoxy}methyl)quinoline; s.c., subcutaneous.
Introduction
The enzyme phosphodiesterase 10A (PDE10A) modulates signal transduction by catabolizing the intracellular second messengers cAMP and cGMP. PDE10A has higher affinity for cAMP and is more efficient with cAMP as substrate (Fujishige et al. 1999; Soderling et al. 1999) . PDE10A is expressed primarily in the brain, particularly in the striatum, nucleus accumbens, and olfactory tubercle, regulating the activity of dopamine-sensitive striatal medium spiny neurons (MSNs) (Loughney et al. 1999; Seeger et al. 2003; Coskran et al. 2006; Sano et al. 2008) .
Striatal MSNs are organized into a dopamine D 1 receptor-expressing "direct" (striatonigral) output pathway and a dopamine D 2 receptor-expressing "indirect" (striatopallidal) output pathway (Graybiel 1990 (Graybiel , 2000 . Action selection and execution takes place via the direct pathway, whereas action suppression is mediated via the indirect pathway (Delong and Wichmann 2007; Wilson 2014) . Both pathways integrate behaviorally relevant information received via cortical and thalamic glutamatergic projections with input regarding the salience of this information from mid-brain dopaminergic neurons (Surmeier et al. 2007 ). Processed information is ultimately fed back to the frontal cortex via both pathways (Delong and Wichmann 2007; Wilson 2014) , which act like the brake and accelerator in a car (Graybiel 2000) .
All currently available antipsychotics block D 2 receptors and, by reducing dopamine-evoked cAMP decrease via Gi-coupled D 2 receptors in the indirect pathway, they activate only the indirect pathway (Kapur and Mamo 2003; Agid et al. 2008) . By increasing cAMP, PDE10A inhibitors (PDEA10Is) activate both the Gi-coupled D 2 receptor-expressing indirect pathway and the Gs-coupled D 1 receptor-expressing direct pathway (Nishi et al. 2008; Strick et al. 2010) , thereby combining functional characteristics of D 2 antagonists and D 1 agonists. Accordingly, PDE10AIs have been proposed as a novel type of antipsychotics with a broader therapeutic profile and reduced side effects (Siuciak et al. 2006; Menniti et al. 2007; Siuciak 2008 ). However, PDE10AIs may have effects beyond D 1 -and D 2 -mediated neurotransmission, also affecting striatal glutamate-NO-guanylyl cyclase signaling (Loughney et al. 1999; Seeger et al. 2003; Coskran et al. 2006; Sano et al. 2008; Grauer et al. 2009 ).
In order to explore their antipsychotic potential and side-effect liability, PDE10AIs have been studied predominantly for effects on stimulated or spontaneous behaviors. In line with results suggesting that PDE10AIs activate indirect pathway neurons to a greater extent than direct pathway neurons (Threlfell et al. 2009; Nishi et al. 2011) , PDE10AIs produce similar effects as D 2 receptor blockers, such as inhibition of spontaneous or stimulant-induced behavior, inhibition of conditioned avoidance behavior and reversal of stimulant-induced sensory gating deficits (Menniti et al. 2007; Schmidt et al. 2008; Grauer et al. 2009; Kehler and Nielsen 2011; Gresack et al. 2013; Megens et al. 2014) . Concomitant direct pathway activation explains the relatively low cataleptogenic activity (Schmidt et al. 2008; Grauer et al. 2009; Megens et al. 2014) , reduced efficiency against behavioral stimulants in case of concomitant D 1 receptor stimulation (Menniti et al. 2007; Sotty et al. 2009; Gresack et al. 2013; Megens et al. 2014) , preferential activity against apomorphineinduced climbing versus apomorphine-induced stereotypy (Grauer et al. 2009 ), cognition-enhancing effects (Rodefer et al. 2005; Grauer et al. 2009 ), and socializing effects (Grauer et al. 2009 ).
The present study investigates effects of PDE10AIs on suppressed behaviors (catalepsy in rats; hypolocomotion in mice) under various conditions of decreased dopaminergic neurotransmission, viz. blockade of D 1 receptors with SCH-23390 (Bourne 2001) , blockade of D 2 receptors with haloperidol, or dopamine depletion with RO-4-1284 (Colzi et al. 1993; Filinger 1994) Grauer et al. 2009; Kehler and Kilburn 2009) . TP-10 is not included in all assays because of limited availability. In some assays, the D 1 agonist SKF-82958 (Wang and McGinty 1997) and the D 2 antagonist haloperidol are also included for comparison. Part of the data have been presented elsewhere (Vanhoof et al. 2012; Megens et al. 2014 ). The present results indicate that PDE10AIs stimulate or suppress motor behavior dependent on the relative activation state of the direct and indirect striatal output pathways.
Materials and Methods

Materials and sources
Company codes refer to the following chemical structures: JNJ-42314415: 3-[6-(2-methoxyethyl)pyridin-3-yl]-2-meth yl-8-morpholin-4-ylimidazo[1,2-a]pyrazine; MP-10: 2-{[4-(1-methyl-4-pyridin-4-yl-1H-pyrazol-3-yl)phenoxy]methyl} quinoline; PQ-10: 6,7-dimethoxy-4-[3-(quinoxalin-2-ylo xy)pyrrolidin-1-yl]quinazoline); RO-4-1284: 2-ethyl-9,10-dimethoxy-3-(2-methylpropyl)-1,3,4,6,7,11b-hexahydro-2H-pyrido[2,1-a] isoquinolin-2-ol; SCH-23390: 8-chloro-3-met hyl-5-phenyl-2,3,4,5-tetrahydro-1H-3-benzazepin-7-ol; SKF-82958: 6-chloro-1-phenyl-3-prop-2-en-1-yl-2,3,4,5-tetrahydro-1H-3-benzazepine-7,8-diol; TP-10: 2-({4-[4-pyridin-4 -yl-1-(2,2,2-trifluoroethyl)-1H-pyrazol-3-yl]phenoxy}methyl) quinoline. All compounds were synthesized in our own laboratories, except apomorphine, D-amphetamine (Certa SA, Eigenbrakel, Belgium), reserpine, and SKF-82958 (Sigma-Aldrich-Fluka, Diegem, Belgium).
Compound administration
Reserpine was dissolved in 10% hydroxypropyl-b-cyclodextrin containing ascorbic acid (4:1 ratio relative to reserpine; w:w). The other compounds were dissolved in water (apomorphine, D-amphetamine), acidified with tartaric acid if required (haloperidol, JNJ-42314415, SCH-23390), or in 10% or 20% hydroxypropyl-b-cyclodextrin acidified with tartaric acid (MP-10, PQ-10, SKF-82958, TP-10). The test formulations were stored at room temperature in closed containers protected from light and subcutaneously (s.c.) administered (10 mL/kg).
Animals (species, weight, and sex)
Male Wistar rats (Crl:WI; 220 AE 50 g) and male NMRI mice (Crl:NMRI(Han); 22 AE 5 g) were obtained from Charles River Breeding Laboratories (Sulzfeld, Germany for rats; L'Arbresle, France for mice) and housed under standard laboratory conditions (21 AE 2°C; 45-65% relative humidity; light-dark cycle set at 12 h). According to standard procedures, all animals were fasted overnight (tap water remaining available ad libitum), allowing oral dosing on an empty stomach (not applicable to the present study). The Institutional Ethics Committee on Animal Experimentation approved the experimental protocols, in compliance with Belgian law (Royal Decree on the protection of laboratory animals 6 April 2010).
Test descriptions
Apomorphine-induced agitation in rats Apomorphine (1.0 mg/kg, i.v., intravenous)-induced agitation was scored (0, 1, 2, or 3) every 5 min over the first hour after injection of apomorphine. Criteria for druginduced inhibition of agitation were: less than six times score 3 (1.5% false positives), less than six times score ≥2 (0.0% false positives), or less than seven times score ≥1 (0.0% false positives).
Observation test in rats
Catalepsy was scored (0, 1, 2 or 3) by two independent observers at 1, 2, 3, and 4 h after administration of test compound or solvent. The catalepsy scores from the two observers were summed for further evaluation. Criteria for drug-induced catalepsy: score >2 for slight catalepsy (occurrence in 1800 control observations: 0.0%; 450 rats and four observations per rat) and score 6 for pronounced catalepsy (not observed in controls). Other abnormalities were considered drug-induced, if occurring in a dose-dependent way. The interactions with SCH-23390 (0.63 mg/kg, s.c.), haloperidol (0.63 mg/kg, s.c.), and RO-4-1284 (10 mg/kg, s.c.) were evaluated by coadministering these agents simultaneously with the test formulations.
Reserpine-induced behavior in rats
Reserpine (10 mg/kg, s.c.) induces miosis, palpebral ptosis, and sedation and blocks the tail-pinch response (the biting and grasping response when an artery clamp is put on the rat's tail, 1 cm from the distal end). The pupil diameter (of the right eye; using a microscopic micrometer; expressed in 1/24 mm units) and the latency of the tailpinch response (s; cutoff time: 120 sec) were measured and palpebral opening (score 0, 1, 2, 3, 4, or 5) and sedation (hypomotility; score 0, 1, 2, 3) were scored 1 h after the reserpine challenge. To assess intrinsic effects of the test compounds, the pupil diameter and the tail-pinch response were also measured just before the reserpine injection. Test compound or solvent was administered 1 h before the reserpine challenge. Based on frequency distributions obtained in a historical control population of solvent-pretreated rats (n = 400), the following all-or-none criteria were selected to assess drug-induced effects: (1) before reserpine injection -induction of miosis: pupil diameter <11 units (4.3% false positive controls; n > 400); induction of mydriasis: pupil diameter >25 units (5.2% false positives); inhibition and blockade of tail-pinch response: latency >45 sec and >120 sec, respectively (5.2% and 0.2% false positives, respectively); (2) after reserpine injection -reversal of the tail-pinch response blockade: latency <120 sec (4.1% false positives); reversal of miosis: pupil diameter >8 units (1.1% false positives); reversal of palpebral ptosis: score for palpebral opening >1 (3.2% false positives); and reversal of sedation: score <3 (1.1% false positives).
Locomotor activity in mice
The procedure room was only sparsely lit (3-30 lx) to provide better contrast for the video tracking. Each locomotor activity arena (gray PVC cylinder; height: 40 cm; diameter: 22.5 cm) was placed on an infrared LED (8 9 8 LEDs) lit box (white PVC squared box; 40 9 40 cm 2 ; height 12.5 cm). An infrared-sensitive tube camera and a white light source (in arena: 4-7 lx) were mounted to the ceiling above the arena to track the animal. Distance travelled was recorded and analyzed using the Noldus Ethovision XT Video Tracking System (Version 3.1; Noldus, Wageningen, the Netherlands). Locomotion was measured over a 30-min period by introducing the mouse into the motor activity arena 30 min after pretreatment with test compound or solvent. The arena was cleaned after each trial. In order to stimulate or suppress locomotion, following treatments were used: D-amphetamine (5.0 mg/kg, s.c.; À0.5 h), SCH-23390 (0.08 mg/kg, i.v.; 0 h), RO-4-1284 (0.63 mg/kg, s.c.; À0.5 h), or haloperidol (0.31 mg/kg, i.v.; 0 h).
General procedure and statistics
General procedure
All experiments were performed by unbiased trained technicians using coded solutions. Doses were selected from the geometrical series 0.01-0.02-0.04. . .40.0-80.0-160 mg/kg. Each dose group consisted of at least five animals which were tested in separate daily experimental sessions in order to account for day-to-day variability and to minimize systematic errors. Control injections of solvent were included in each experimental session. In Figures 4-6, dose 0 mg/kg refers to results obtained in solvent-treated control animals that were tested concurrently with the test compounds.
ED 50 determination
All-or-none criteria for drug-induced effects were defined by analyzing a frequency distribution of a series of historical control data, aiming for less than 5% responders in the control population. The fraction of animals responding to these criteria in animals pretreated with test compound was determined per dose level (n ≥ 5 in the relevant dose range; at least three doses). ED 50 s (the dose inducing the defined effect in 50% of the tested animals) and corresponding 95% confidence limits were determined according to the modified Spearman-Karber estimate, using theoretical probabilities instead of empirical ones (Tsutakawa 1982) . This modification allows estimation of the ED 50 and its confidence interval as a function of the slope of the log dose-response curve (Lewi et al. 1977) .
Time-activity relationship
ED 50 s were plotted versus time after dosing using GraphPad Prism â (software version 5.00 for Windows, GraphPad Software, San Diego, CA; www.graphpad.com). The ED 50 at time of peak effect and the onset and duration of action (at four times the peak-effect dose) were estimated from the curve of best fit through these data points as generated by nonlinear regression of the polynomial second order function y = a + bx + cx 2 . Goodness of fit was determined by calculating R 2 and S y.x .
Results
Apomorphine-induced agitation in rats
Inhibition of apomorphine-induced behavior relates to the D 2 receptor blocking activity of antipsychotics (Leysen and Niemegeers 1985; Leysen 2000) . Apomorphine antagonism was used in the present study as sensitive index for the functional D 2 antagonism of PDE10AIs in rats, being measured at doses close to the ED 50 for striatal PDE10A occupancy (Megens et al. 2014) . The ED 50 s of JNJ-42314415, PQ-10, TP-10, and MP-10 obtained for inhibition of apomorphine-induced behavior at various time intervals after s.c. injection are listed in Table 1 and graphically presented in Figure 1 (solid circles; the other data are discussed below). The PDE10AIs showed a fast onset of action (<0.5 h) and reached their peak effect within 0.5-1 h (nonlinear regression estimates in Table 2 ). JNJ-42314415, MP-10, and TP-10 were about equipotent and about three to four times more potent than PQ-10 in terms of peak-effect dose. MP-10 showed a somewhat shorter duration (2.8 h) than the other compounds (4.3-4.8 h). (mg/kg)
Time ( 6). In rats cotreated with SCH-23390 ( Fig. 2 : bottom panel for each compound; closed circles), however, the PDE10AIs consistently induced pronounced catalepsy (score 6). The dose-response curves were bell-shaped: catalepsy decreased again at higher dose levels, being replaced by stereotyped sniffing and rearing. The ED 50 s for the various effects in rats cotreated with SCH-23390 (Table 3) The time course for the effects in the rats cotreated with SCH-23390 was found to proceed more or less in parallel with the apomorphine antagonism in the absence of SCH-23390. In the rats cotreated with SCH-23390, the PDE10AIs already induced catalepsy at low doses comparable to those for apomorphine antagonism (Table 4) , reflecting a very small safety margin under these conditions. SCH-23390 (0.63 mg/kg, s.c.) alone did not induce catalepsy (score >2 was observed only once in 35 rats tested at four time intervals). As the functional D 1 agonism of PDE10AIs apparently counteracts the catalepsy that may be expected from their functional D 2 antagonism, it is studied below whether this activity component may also counteract catalepsy and related behaviors induced by other mechanisms, viz. D 2 receptor blockade with haloperidol or dopamine depletion using Ro-4-1284 or reserpine.
Interaction with the D 2 antagonist haloperidol Figure 3 illustrates the dose-dependent reversal of haloperidol (0.63 mg/kg, s.c.)-induced catalepsy after cotreatment with JNJ-42314415, TP-10, MP-10, and the D 1 agonist SKF-82958. Shown are individual data and median scores per dose group obtained 2, 3, and 4 h after dosing. In solvent-cotreated rats (n = 321), haloperidol consistently induced catalepsy, which became more pronounced at later time intervals. Catalepsy scores <2 at 2 h and <5 at 3 h and 4 h occurred in only 6.2%, 4.7%, and 3.1% of these control rats, respectively, and were adopted as critical levels for reversal of haloperidol-induced catalepsy (dotted horizontal lines in Fig. 3 ). The three PDE10AIs dose dependently reversed the haloperidolinduced catalepsy (Fig. 3 , Table 5 ). The lowest ED 50 obtained over the three time intervals was 4.7 mg/kg for JNJ-42314415, 2.69 mg/kg for TP-10, and 6.2 mg/kg for MP-10, corresponding to 4.9, 2.5, and 7.0 times, respectively, the ED 50 for apomorphine antagonism at time of peak effect (Table 2) . SKF-82958 reversed haloperidolinduced catalepsy at 1 h with a bell-shaped dose-response curve (estimated ED 50 : 1.02 mg/kg) but was hardly effective at the later time intervals.
Interaction with the monoamines-depleting agent RO-4-1284 RO-4-1284 (10 mg/kg, s.c.) consistently induced catalepsy and sedation in solvent-cotreated rats (n = 50). JNJ-42314415, PQ-10, and MP-10 dose dependently reversed the RO-4-1284-induced sedation and catalepsy, which were replaced by behavioral excitation (Table 6-8; Fig. 4 ). The effects occurred as doses close to the ED 50 for apomorphine antagonism (Table 9 ). The D 1 agonist SKF-82958 tended to reverse the RO-4-1284-induced catalepsy at 2.5 mg/kg without affecting sedation. At this dose, however, the combination with RO-4-1284 resulted in convulsions, spasms and body twitches in two of the five rats tested (one of them died and was not included in Table 10 ).
Interaction with the monoamines-depleting agent reserpine
Reserpine (10 mg/kg, s.c.) induced palpebral ptosis, sedation, and blocked the tail-pinch response (the grasping and biting response when an artery clamp is put on the distal end of the rat's tail; latency >120 sec). Before the reserpine challenge, the PDE10AIs inhibited the tail-pinch The values were interpolated from the nonlinear regression lines in response per se (latency >45 sec) at doses only 1.2-3.2 times the ED 50 for apomorphine antagonism (Fig. 5 , Table 11 ). The dose-response relations for the inhibition of the tail-pinch response tended to be bell-shaped, except for PQ-10 (tested in a small dose range only). While inhibiting the tail-pinch response before reserpine, the PDE10AIs in contrast dose dependently reversed the reserpine-induced blockade of the tail-pinch response 1 h after reserpine. This effect occurred at 3.3-8.5 times the ED 50 for apomorphine antagonism. The PDE10AIs even restored normal response latencies (<45 sec) at slightly higher doses (5.0-11 times the ED 50 for apomorphine antagonism). Reversal of the reserpine-induced tailpinch response blockade was thus observed at similar doses as those inhibiting the tail-pinch response before reserpine (Table 11 ). The PDE10AIs also reversed the reserpine-induced sedation (at 0.54-3.2 times the ED 50 for apomorphine antagonism; Fig. 6 ), which was replaced by behavioral stimulation (sniffing and rearing) at 1.9-4.9 times the ED 50 for apomorphine antagonism. The PDE10AIs also tended to reverse the reserpine-induced palpebral ptosis (at 0.96-3.2 times the ED 50 for apomorphine antagonism) but did not affect pupil diameter up to the highest doses tested (data not shown). Before the reserpine challenge, the D 1 agonist SKF-82958 inhibited the tail-pinch response in some rats (from 0.16 mg/kg onward; maximum 40% responders), presumably related to behavioral stimulant effects (sniffing, rearing; ED 50 Table 11 ), and tended to normalize the tail-pinch response (estimated ED 50 : 0.51 mg/kg;) and to reverse the ptosis (from 0.31 mg/kg onward; data not shown) without affecting miosis (ED 50 : >10 mg/kg; data not shown). The overt behavioral stimulation seen with SKF-82958 before the reserpine challenge was not seen after the reserpine challenge (Table 11 ). In contrast, the PDE10AIs showed behavioral stimulant effects after but not preceding the reserpine challenge.
Locomotor activity assays in mice
In addition to the above studies at the level of catalepsy in rats, similar studies were performed at the level of locomotion in mice. First, inhibition of D-amphetamineinduced hyperlocomotion was tested as index of functional D 2 antagonism. Subsequently, the ability of PDE10AIs to reverse the hypolocomotion induced by the D 1 antagonist SCH-23390, the monoamines-depleting agent, Ro-4-1284, or the D 2 antagonist haloperidol was evaluated. Total distance travelled in solvent-pretreated control mice receiving no challenge was 4167 AE 1135 cm (mean AE SD; n = 1444).
Inhibition of hyperlocomotion induced by the dopamine-releasing agent D-amphetamine
In solvent-pretreated control mice, D-amphetamine (5.0 mg/kg, s.c.;À0.5 h) increased distance travelled to 12,764 AE 4278 cm (mean AE SD; n = 462). Only 3.0% of these control mice travelled <5500 cm. The PDE10AIs and the D 2 receptor blocker haloperidol reduced the D-amphetamine-induced hyperlocomotion in a dosedependent manner to normal values <5500 cm (Fig. 7 , first column; ED 50 s in Table 12 , first column).
Reversal of hypolocomotion induced by the D 1 antagonist SCH-23390
In solvent-pretreated control mice, SCH-23390 (0.08 mg/kg, i.v., 0 h) decreased distance travelled to 1408 AE 513 cm (mean AE SD; n = 279). Only 1.4% of these SCH-23390-challenged control mice travelled a distance >2500 cm. The PDE10AIs and the D 1 agonist SKF-82958 reversed the SCH-23390-induced hypolocomotion to normal values (>2500 cm; Fig. 7 ; second column). The ED 50 s of the PDE10AIs for this effect were similar to those required for inhibition of D-amphetamine-induced hyperlocomotion (Table 12) .
Reversal of hypolocomotion induced by the monoamines-depleting agent RO-4-1284
In solvent-pretreated control mice, dopamine depletion with RO-4-1284 (0.63 mg/kg, s.c., À0.5 h) induced pronounced hypolocomotion (total distance [mean AE SD]: 772 AE 411 cm; n = 218). Values >2500 cm were rarely measured (in only 0.4% of the control mice). The tested PDE10AIs and the D 1 agonist SKF-82958 reversed the RO-4-1284-induced hypolocomotion to normal values (>2500 cm; Fig. 7 ; third column). The dose-response curves of JNJ-42311445 and PQ-10 tended to be bell-shaped and effect size tended to be higher for MP-10 than for JNJ-42311445 and PQ-10. The PDE10AIs were somewhat (two to three times) more potent against Ro-4-1284 than against D-amphetamine or SCH-23390 while SKF-82958 was equipotent in both assays (Table 12) . Values >2500 cm occurred in only 4.0% of these control mice. The PDE10AIs and the D 1 agonist SKF-82958 were not able to reverse the haloperidol-induced hypolocomotion to values >2500 cm, except for a tendency in the lower dose range of the PDE10AIs (maximum percentage responders: 60% at 10 mg/kg for JNJ-42314415; 40% at 10 mg/kg for PQ-10, 40% at 0.63 mg/kg for MP-10, and 0% for TP-10).
Discussion
PDE10AIs resemble D 2 receptor blockers by, for example, inhibiting spontaneous and stimulant-induced behavior, inhibiting conditioned behavior, and reversing stimulantinduced sensory gating deficits (see Introduction). These effects are mediated by indirect pathway activation, partially counteracted by direct pathway activation when D 1 receptors are concomitantly stimulated (Menniti et al. 2007; Gresack et al. 2013; Megens et al. 2014) . By stimulating dopamine D 2 receptors, nonselective dopamine Median catalepsy scores of successive dose groups have been interconnected. The horizontal dotted lines represent the critical levels adopted for slight catalepsy (score >2) and pronounced catalepsy (maximum score 6). The PDE10AIs consistently induced pronounced catalepsy with bellshaped dose-response curves in the rats cotreated with the D 1 antagonist, whereas they induced almost no or only slight catalepsy in the rats not cotreated with the D 1 antagonist. PDE10AI, phosphodiesterase 10A inhibitor. activation Schmidt et al. 2008; Megens et al. 2014) . After D 1 receptor blockade with SCH-23390, however, PDE10AIs induced pronounced catalepsy at low doses comparable to those required for inhibition of apomorphine-induced behavior. Similar levels of catalepsy occur with D 2 receptor blockers only at >10-fold higher dose increments . The potentiation of PDE10AI-induced catalepsy by a D 1 antagonist confirms that PDE10AIs suppress central D 2 receptor-mediated neurotransmission very efficiently The number of rats responding to the listed criterion is listed per dose level (n = 5 per dose). Values representing more than 50% responders are formatted bold. The number of rats responding to the listed criterion is listed per dose level (n = 5 per dose group). Values representing more than 50% responders are formatted bold. when concomitant direct pathway activation is prevented by D 1 receptor blockade and implies a risk of increased EPS when combining a PDE10AI with a neuroleptic with associated D 1 antagonism (e.g., clozapine or olanzapine; Schotte and Leysen 1998).
The time course for catalepsy in animals cotreated with SCH-23390 was found to proceed more or less in parallel with inhibition of apomorphine-induced behavior in the absence of SCH-23390. This confirms previously reported data on the time course of (mild) catalepsy after 
The number of rats responding to the listed criterion is listed per dose level (n = 5 per dose group). Values representing more than 50% responders are formatted bold.
1
Percentage of false positives (solvent-pretreated rats responding to the criterion [n = 50]). PDE10AIs alone Schmidt et al. 2008) . However, catalepsy after D 2 receptor blockers intensifies over time with retesting of the animals (Stanley and Glick 1976; Hillegaart et al. 1987) , this is apparently not the case after PDE10AIs. The reversal of haloperidol-induced catalepsy by PDE10AIs in the present study apparently conflicts with the reported potentiation of haloperidolinduced catalepsy after the PDE10AI papaverine (Siuciak et al. 2006) . When a lower dose of haloperidol was used, however, we also showed PDE10AI-induced potentiation of catalepsy but only at low doses with a bell-shaped dose-response relation (Vanhoof et al. 2012 ). The present data show that PDE10AI-induced direct pathway activation also counteracts catalepsy and related behaviors induced by reducing D 2 receptor-mediated neurotransmission via other mechanisms such as blockade of D 2 receptors with haloperidol or dopamine depletion with RO-4-1284 or reserpine. The PDE10AIs were somewhat less potent against haloperidol than against RO-4-1284 or reserpine, presumably because they had to overcome the D 2 receptor blockade by haloperidol, whereas D 2 receptors are functioning normal after dopamine depletion. Moreover, a switch in receptor-mediated signal transduction mechanism to a supersensitive form of D 1 -mediated neuronal plasticity has been demonstrated in the dopamine-depleted striatum (Gerfen 2000) .
The opposing effects of PDE10AIs in the reserpine test are striking. PDE10AIs inhibit the tail-pinch response Figure 4 . Reversal of Ro-4-1284 (10 mg/kg, s.c.)-induced catalepsy in rats that were cotreated (at the same time) with the PDE10AIs JNJ-42314415, PQ-10, or MP-10 or the dopamine D 1 agonist SKF-82958. Shown are individual and median catalepsy scores (symbols and stripes, respectively) per dose group measured 2, 3, and 4 h after dosing. The dotted horizontal lines represent the critical levels adopted for druginduced reversal of catalepsy (score <2 at 2 h; score <5 at 3 and 4 h) that were used for the determination of the ED 50 values listed in Tables 6-8, 10 . The PDE10AIs dose dependently reduced catalepsy scores to below the critical level. The D 1 agonist was effective at the 2-h interval and, to a lesser extent, at the 3-h time interval. PDE10AI, phosphodiesterase 10A inhibitor.
before reserpine at doses close to the ED 50 for apomorphine antagonism, presumably via indirect pathway activation. After reserpine, however, only slightly higher doses induce the opposite effect, viz. reversal of the reserpine-induced tail-pinch response blockade, presumably via direct pathway activation. In other words, indirect or direct pathway activation predominates under condition of normal and low dopaminergic neurotransmission, respectively. The anticataleptic properties of PDE10AIs at conditions of low dopaminergic transmission may suggest therapeutic potential in Parkinson's disease. The anticataleptic effects are mediated via direct pathway activation, an effect that is shared with D 1 agonists. D 1 agonists have therapeutic potential in Parkinson's disease but suffer from side effects (Mailman et al. 2001; Hurley and Jenner 2006) . In view of minimal expression of PDE10A in peripheral tissue (Seeger et al. 2003; Coskran et al. 2006) , PDE10AIs are likely devoid of the disturbing peripheral cardiovascular side effects of direct D 1 receptor agonists (Westfall and Westfall 2005) .
The results obtained in mice further substantiate the results obtained in rats. Like haloperidol, the PDE10AIs inhibited D-amphetamine-induced hyperlocomotion, attesting to their functional D 2 antagonism. At similar doses, the PDE10AIs also counteracted the hypolocomotion The ratio over the corresponding ED 50 for apomorphine antagonism is listed between square brackets. The number of rats responding to the listed criterion is listed per dose level (n = 5 per dose group). Values representing more than 50% responders are formatted bold.
One of the five rats tested at 2.5 mg/kg died and was not included. . Shown are individual and median response latencies (symbols and stripes, respectively) per dose group measured immediately before and 1 h after the reserpine challenge. The dotted and solid horizontal lines represent the critical latencies adopted for inhibition and blockade of the tail-pinch response (>45 sec and >120 sec, respectively) that were used for the determination of ED 50 values listed in Table 11 . The PDE10AIs inhibited the tail-pinch response before the reserpine challenge with an apparently bell-shaped dose-response relation, whereas they reversed the reserpine-induced blockade of the tail-pinch response 1 h after the reserpine challenge. The D 1 agonist only tended to inhibit the tail-pinch response before reserpine but efficiently reversed the reserpine-induced blockade of the tail-pinch response 1 h after the reserpine challenge. PDE10AI, phosphodiesterase 10A inhibitor. and RO-4-1284 are most likely related to direct pathway activation.
The minor effects obtained with the D 1 agonist SKF-82958 in rats do not fully support the hypothesis that common direct pathway activation mediates the effects of PDE10AI against the sedation and catalepsy induced by haloperidol, RO-4-1284, and reserpine. SKF-82958 antagonized haloperidol-induced catalepsy only at the 2-h interval but this may be related to short duration of action (Desai et al. 2005) . However, the D 1 agonist also reversed the reserpine-induced effects only partially and tended to reverse RO-4-1284-induced catalepsy only at very high doses. The effect on D 1 signaling under these conditions is apparently more efficient with a PDE10AI than that with an orthosteric D 1 agonist. This may be the case because, under dopamine depletion, D 1 receptors become supersensitive resulting from a signaling switch from induction of immediate early genes (such as c-fos) toward ERK/MAP signaling (Gerfen et al. 2002) , whereas PDE10AIs induce both immediate early genes and ERK/MAP signaling (Strick et al. 2010) .
Behavioral stimulant effects of PDE10AIs were observed in combination with high doses of the D 1 antagonist SCH-23390 or the dopamine-depleting agents RO-4-1284 or reserpine but not in combination with the D 2 receptor blocker haloperidol. Like D 2 receptor blockers, PDE10AIs increase striatal dopamine turnover (Schmidt et al. 2008) . In contrast to D 2 receptor blockers, however, PDE10AIs do not directly prevent D 2 receptor stimulation, thereby leaving dopaminergic neurotransmission largely intact. Thus, the above behavioral stimulant effects of PDE10AIs may arise from progressively increasing activation of the direct pathway overcoming the effect of D 1 receptor blockade and resulting in behavioral stimulation as long as the indirect pathway is not disinhibited by D 2 receptor blockade. The behavioral stimulant effects are observed at doses close to those required for reversal of the cataleptic state, reflecting very efficient direct pathway activation and limited safety margin for anti-Parkinson effects. Concomitant direct pathway activation may also explain the bell-shaped dose-response for inhibition of the tail-pinch response before reserpine. Similar bell-shaped effects on glucose metabolism in the lateral habenula of mice were also attributed to increased direct pathway activation at high PDE10AI doses (Dedeurwaerdere et al. 2011) .
Balance between direct and indirect pathway activation is necessary for numerous behaviors including reward processing (Lobo et al. 2010; Beutler et al. 2011) . Dopamine D 1 receptors in the direct striatal pathway facilitate several dopamine-dependent functions including appetitive behaviors. Global loss of dopamine D 1 receptors demonstrates its importance for feeding and reward acquisition to the general ability to thrive (Drago et al. 1994; Xu et al. 1994; Wall et al. 2011) . In this regard, direct striatal pathway activation by PDE10AIs might improve negative and depressive symptomatology in schizophrenic patients. In view of the monoamine hypothesis of depression (Hirschfeld 2000) , the antidepressant potential of PDE10AIs may be supported by the reversal of the effects of monoamines depletion observed in the present study. Together with previously reported data, the present results indicate that PDE10AIs suppress stimulant behavior via indirect pathway activation, but the effect is counteracted by D 1 receptor stimulation and corresponding activation of the direct pathway. In the absence of counteracting direct pathway activation (D 1 receptor stimulation), however, this mechanism is very efficient, resulting in a limited safety margin toward cataleptic side effects. Conversely, PDE10AIs can reverse behavioral suppression (catalepsy, hypolocomotion) via direct pathway activation, but the effect is counteracted by D 2 receptor blockade and corresponding disinhibition of the indirect pathway. In the absence of concomitant, counteracting indirect pathway activation (D 2 receptor blockade), however, this Figure 6. Dose-dependent reversal of reserpine-induced sedation and replacement by excitation. Shown are individual and median scores (symbols and stripes, respectively) for sedation and excitation (measured 1 h post reserpine) in rats pretreated with the PDE10AIs JNJ-42314415, PQ-10, MP-10, and the D 1 agonist SKF-82958 1 h before the reserpine challenge. The dotted horizontal lines represent the critical score adopted for reversal of sedation (score <3). In case of excitation, score >0 was used for the determination of ED 50 values. The PDE10AIs dose dependently reversed the reserpine-induced sedation, which was replaced by excitation. The D 1 agonist also reversed the reserpine-induced sedation but without resulting in excitation. PDE10A, phosphodiesterase 10A inhibitor.
mechanism is very efficient with a limited safety margin toward behavioral stimulant side effects. In analogy, the brake and accelerator of a car also function more efficiently when used separately rather than simultaneously, yet both are indispensable to adjust speed when out of balance. Further clinical studies have to show which patients may benefit from the dual activity profile of PDE10AIs. 
